Biotricity, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Redwood city, ca / accesswire / april 30, 2024 / biotricity inc. (nasdaq:btcy), a groundbreaking technology-as-a-service (taas) company committed to delivering cutting-edge medical and consumer diagnostic healthcare solutions, announces the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues.

Redwood city, ca / accesswire / april 26, 2024 / biotricity inc. (nasdaq:btcy), a pioneering technology-as-a-service (taas) company dedicated to delivering top-of-the-line medical diagnostic and consumer healthcare solutions, announces high demand for its latest breakthrough device, biotres pro. this device is easy to wear, resulting in excellent patient compliance and a higher selling price.

Redwood city, ca / accesswire / april 18, 2024 / biotricity inc. (nasdaq:btcy) a leading technology-as-a-service (taas) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes.

Redwood city, ca / accesswire / april 16, 2024 / biotricity inc. (nasdaq:btcy) ("biotricity" or the "company"), a leading technology-as-a-service (taas) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. the pilot program will demonstrate the value of biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network.

Redwood city, ca / accesswire / april 2, 2024 / biotricity inc. (nasdaq:btcy) ("biotricity" or the "company"), a leading technology-as-a-service (taas) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues. there are over 1,000 neurological disorders and over 100 million americans suffering from at least 1 neurological issue.

After losing some value lately, a hammer chart pattern has been formed for Biotricity (BTCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Biotricity Inc. (BTCY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Biotricity Inc. (BTCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago.

REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakeven Management to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024 REDWOOD CITY, CA / ACCESSWIRE / February 14, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency. For the Third Quarter of Fiscal Year 2024, the Company expects to announce: Record gross margins of 73% compared to the prior year quarter of 57% Improved operational efficiency, reflected in a reduction in operating expenses of over 30% The results for our third quarter will demonstrate year-over-year improvements in all key operating metrics- specifically in operational costs and gross margins.

Biotricity, Inc. (NASDAQ:BTCY ) Q2 2024 Earnings Conference Call November 14, 2023 6:00 PM ET Company Participants Debra Chen - IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Davin - H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2024 Financial Results and Business Update Conference Call.

Biotricity improves margins while lowering selling expenses and operating losses REDWOOD CITY, CA / ACCESSWIRE / November 10, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Biotricity (NASDAQ:BTCY ) Q1 2024 Earnings Conference Call August 15, 2023 4:30 PM ET Company Participants Debra Chen – Investor Relations Waqaas Al-Siddiq – Founder and Chief Executive Officer John Ayanoglou – Chief Financial Officer Conference Call Participants Kevin Dede – H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's First Quarter Fiscal 2024 Financial Results and Business Update Conference Call.

REDWOOD CITY, CA / ACCESSWIRE / August 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its First Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, August 15, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.